Evidence map›Paper›PMID 39699678›Full record

ArticleEuropean radiology2025

A visual scale to rate amygdalar atrophy on MRI.

Francesca B Pizzini, Federica Ribaldi, Valerio Natale, Max Scheffler, Vittoria Rossi, Giovanni B Frisoni

Abstract read
In one paragraph

Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Clinical and molecular correlates of limbic age-related TDP-43 encephalopathy (LATE)European journal of nuclear medicine and molecular imaging · 2025
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Francesca B Pizzini *Radiology and Department of Engineering for Innovation Medicine, Verona University, Verona, Italy. francescabenedetta.pizzini@univr.it.ORCID http://orcid.org/0000-0002-6285-0989
Federica Ribaldi *Geneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland.
Valerio NataleDepartment of Diagnostic and Public Health, Rivoli Hospital, Rivoli (TO), Italy.
Max SchefflerDivision of Radiology, Geneva University Hospitals, Geneva, Switzerland.
Vittoria RossiRadiology and Department of Engineering for Innovation Medicine, Verona University, Verona, Italy.
Giovanni B FrisoniGeneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland.

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
NIA NIH HHS U01 AG024904Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 320030_182772
6 · The paper itself

Abstract

backgroundVisual rating scales are routinely used in clinical radiology to assess brain atrophy on scans of patients with suspected neurodegenerative conditions. Limbic predominant age-related TDP-43 encephalopathy (LATE) has recently been described, featuring early and severe atrophy of the amygdala. However, there is currently no scoring system specifically designed to assess amygdalar atrophy on MRI.

objectivesto develop and validate a visual rating scale for amygdalar atrophy. MATERIALS AND

methodsStringent criteria were developed for no, mild/moderate, and severe amygdalar atrophy based on axial and coronal volumetric T1-weighted MRI scans. Inter- and intra-rater reliabilities were estimated by three independent expert neuroradiologists in 100 randomly selected scans from the Geneva Memory Center cohort selected to be representative of the variability of medial temporal atrophy. Convergent validity was evaluated versus amygdalar volumes extracted by FreeSurfer on 1943 consecutive patients. Criterion validity versus autopsy-confirmed LATE neuropathologic changes were studied in the pathological subset of the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort (N = 96).

resultsIntra- and inter-rater agreements of amygdalar visual ratings were between substantial and almost perfect (weighted Cohen's Kappa 0.71 to 0.93). Visual ratings were strongly associated with amygdalar volumes (p ≤ 0.001 on the Kruskal-Wallis test). LATE neuropathologic changes were associated with visual ratings of amygdalar atrophy (p = 0.057 on a test for trend).

conclusionThe proposed visual amygdalar atrophy scale is a reliable and valid tool to assess amygdalar atrophy on MRI and can be a useful adjunct in routine radiological reporting. KEY POINTS: Question Assessment of amygdalar atrophy is crucial for diagnosing neurodegenerative diseases, as the limbic predominant age-related TDP-43 encephalopathy, yet no validated visual rating scale exists. Findings The proposed amygdalar atrophy scale demonstrated high intra-rater and inter-rater reliability, strong correlation with amygdalar volumetry, and association with limbic predominant age-related TDP-43 encephalopathy (LATE). Clinical relevance The amygdalar atrophy scale provides a reliable practical assessment tool that enhances diagnostic accuracy for dementia-related conditions, particularly aiding in identifying limbic predominant age-related TDP-43 encephalopathy.

Indexed as

AmygdalaMagnetic Resonance ImagingAgedAged, 80 and overAlzheimer DiseaseAtrophyFemaleHumansMaleMiddle AgedReproducibility of ResultsAmygdalaAtrophyDementiaMRI

Identifiers

PMID39699678
PMCPMC12165972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.